COMORBIDITY IMPACT ON SOCIAL FUNCTIONING AFTER HIP FRACTURE: THE ROLE OF REHABILITATION

NATASA RADOAVLJEVIC¹,², DEJAN NIKOLIC²,³, MILICA LAZOVIC¹,², MARIJA HRKOVIC¹, OLIVERA ILC-STOJANOVIC¹,²

INTRODUCTION

Objective: To analyze the impact of rehabilitation treatment on social functioning in elderly patients after hip fracture during a rehabilitation program. Methods: This study included 203 patients with hip fracture. Four groups were analyzed on rehabilitation: Group 1, at admission, Group 2, at discharge, Group 3, three months after discharge and Group 4, six months after discharge. The analyzed parameters included: musculoskeletal, neurological and cognitive impairments. Impairment severity was graded by cumulative index grading scale for geriatrics (CIRS-G). Evaluation of social functioning was completed by social functioning component (SFC) from quality of life (SF-36) questionnaire. Results: There was a significant improvement in SF-36 SFC values for observed impairments from admission to six months after discharge for each severity degree (p<0.01), except for CIRS-G severity degree 4 for cognitive impairment, where significance was p<0.05. For the group of patients with musculoskeletal impairment, there was a significant difference between the values of SF-36 SFC concerning different severity degrees of CIRS-G only at six months after discharge (p<0.05). Patients with neurological or cognitive impairments have shown significant differences between the values of SF-36 SFC in regard to severity degrees of CIRS-G in all observational groups. Conclusion: Different degrees of observed impairments influence the degree of social functioning recovery in the elderly after hip fracture. Level of Evidence II, Prognostic Studies.

Keywords: Hip fracture. Rehabilitation. Elderly. Follow-up studies.

MATERIAL AND METHODS

We performed longitudinal study that included 203 patients with hip fracture that were referred to Institute for Rehabilitation for post acute rehabilitation treatment after hip fracture. Prior to inclusion in the study, eligible participants were informed about the study protocol and patients’ permissions were obtained. The study was approved by Institutional Review Board of Faculty of Medicine (440/IV-6) and followed the principles of good clinical practice. Patients were grouped into four groups regarding the time of evaluation: Group 1- included patients at admission, Group 2- at discharge, Group 3- on 3 months post discharge and Group 4- on 6 months post discharge. Further impairments were analyzed: musculoskeletal, neurological and cognitive. For the gradation of impairment severity we used Cumulative index rating scale for geriatrics (CIRS-G) in the range between 0-4, where 0- refers to the condition with no impairment, 1- refers to mild, 2- moderate, 3- severe and 4- extremely severe impairment. For the evaluation of social functioning we used the social functioning component (SFC) from quality of life (SF-36) questionnaire.

All the authors declare that there is no potential conflict of interest referring to this article.
Statistical interpretation

Patients distribution was presented as mean values (MV) with standard deviation (SD) for different degree of CIRS-G for every evaluated parameter (musculoskeletal, neurological and cognitive) in different times of observation. For the evaluation of statistical difference among these parameters we performed one-way ANOVA and Mann-Whitney U test. Pearson’s correlation coefficient was used to assess degree of correlation for every study parameter and same CIRS-G degree, between different times of observation. In order to evaluate and quantify variability that can be explained between different CIRS-G severity degrees and the values of social functioning of SF-36 questionnaire for analyzed CIRS-G parameters (musculoskeletal, neurological and cognitive) we introduced \( r^2 = \text{Sum of squares (Between groups)} / \text{Sum of squares (Total)} \times 100 \), where sum of squares were gained from the one-way ANOVA test and results were presented as percentage (%).

Oneway ANOVA was used to evaluate statistical significance among different CIRS-G degrees at the same time of observation for every study parameter. Statistical significance was set at \( p < 0.05 \).

RESULTS

Evaluating defined severity degrees of CIRS-G in all groups of defined time periods (Groups 1-4) we found no significant differences in mean values of SF-36 SFC among musculoskeletal, neurological and cognitive impairments. (Table 1) Non significantly lowest values for SF-36 SFC is noticed for severity degree 4 for subjects with neurological impairment (SFC\textsubscript{Group4}=9.10±12.03) at admission. (Table 1) In this study there were no subjects with severity degree 4 of CIRS-G with musculoskeletal impairment. (Table 1) Non significantly highest values for SF-36 SFC is noticed for severity degree 0 for subjects with musculoskeletal impairment (SFC\textsubscript{Group0}=75.11±21.95), neurological impairment (SFC\textsubscript{Group1}=72.80±23.96) and cognitive impairment (SFC\textsubscript{Group2}=77.47±19.86) 6 months post discharge. (Table 1).

There is a significant improvement shown to be in SF-36 SFC values for observed impairments throughout follow-up, from admission to 6 months post discharge for every severity degree at the level of \( p < 0.01 \), except for CIRS-G severity degree 4 for cognitive impairment, where significance was at level \( p < 0.05 \). (Table 2).

In Table 3, there is a significant correlation of SF-36 SFC shown to before musculoskeletal, neurological and cognitive impairments for same severity degree of CIRS-G in different times of observations. The highest correlation coefficient for the group with musculoskeletal impairment is for CIRS-G severity degree 1, between Group 2 and Group 3 (\( R = 0.919 \)), for subjects with neurological impairment for CIRS-G severity degree 2, between Group 1 and Group 2 (\( R = 0.919 \)) and for subjects with cognitive impairment for CIRS-G severity degree 2, between Group 2 and Group 3 (\( R = 0.936 \)). (Table 3)

For the group of patients with musculoskeletal impairment there is a significant difference between the values of SF-36 SFC concerning different severity degrees of CIRS-G only 6 months post discharge (Group 4; \( p < 0.05 \)). (Table 4) While for the subjects with neurological or cognitive impairments, there is a significant

### Table 1. SF-36 SFC mean values in different time of observation for separate CIRS-G parameters regarding severity degree.

| Evaluated groups | CIRS-G (degree) | Musculoskeletal impairment | Neurological impairment | Cognitive impairment | \( p \) value |
|------------------|----------------|---------------------------|------------------------|---------------------|-------------|
| Group 1 (MV ± SD) | 0   | 28.07 ± 13.15             | 28.13 ± 14.66          | 30.16 ± 14.06       | 0.474      |
|                  | 1   | 26.13 ± 16.39             | 27.21 ± 14.81          | 26.88 ± 14.86       | 0.952      |
|                  | 2   | 24.93 ± 13.51             | 20.54 ± 13.52          | 21.31 ± 11.74       | 0.417      |
|                  | 3   | 24.91 ± 14.18             | 20.59 ± 12.45          | 18.75 ± 10.72       | 0.249      |
|                  | 4   | -                         | 13.75 ± 7.56           | 9.10 ± 12.03        | 0.267      |
| Group 2 (MV ± SD) | 0   | 51.60 ± 13.98             | 50.29 ± 15.90          | 53.06 ± 14.33       | 0.345      |
|                  | 1   | 48.67 ± 18.40             | 50.00 ± 17.68          | 48.75 ± 17.40       | 0.962      |
|                  | 2   | 46.28 ± 14.98             | 46.43 ± 15.06          | 43.75 ± 14.68       | 0.774      |
|                  | 3   | 44.40 ± 14.79             | 42.29 ± 12.78          | 37.50 ± 12.86       | 0.253      |
|                  | 4   | -                         | 29.69 ± 11.45          | 30.30 ± 14.59       | 0.968      |
| Group 3 (MV ± SD) | 0   | 64.96 ± 18.16             | 63.28 ± 20.16          | 67.34 ± 17.04       | 0.232      |
|                  | 1   | 58.50 ± 23.63             | 61.77 ± 21.41          | 60.31 ± 20.19       | 0.828      |
|                  | 2   | 59.60 ± 19.58             | 51.79 ± 23.44          | 54.21 ± 22.80       | 0.422      |
|                  | 3   | 56.71 ± 21.56             | 52.21 ± 20.84          | 45.83 ± 18.69       | 0.221      |
|                  | 4   | -                         | 37.50 ± 16.37          | 27.80 ± 19.35       | 0.230      |
| Group 4 (MV ± SD) | 0   | 75.11 ± 21.95             | 72.80 ± 23.96          | 77.47 ± 19.86       | 0.252      |
|                  | 1   | 64.63 ± 27.71             | 63.24 ± 27.41          | 69.06 ± 22.64       | 0.630      |
|                  | 2   | 69.79 ± 25.13             | 56.21 ± 28.02          | 57.69 ± 31.04       | 0.143      |
|                  | 3   | 59.57 ± 26.96             | 57.35 ± 25.79          | 45.14 ± 21.07       | 0.153      |
|                  | 4   | -                         | 34.36 ± 17.36          | 29.45 ± 22.07       | 0.478      |

*Oneway ANOVA. **Mann-Whitney U test.
difference between the values of SF-36 SFC in regard to severity degrees of CIRS-G in all observational groups (Groups 1-4). (Table 4) The effects size of the CIRS-G severity degree on SF-36 SFC values is weaker for all comorbidity parameters in the group at admission (musculoskeletal impairment-$\eta^2_{\text{Group 1}}=0.75$; neurological impairment-$\eta^2_{\text{Group 1}}=6.49$ and cognitive impairment-$\eta^2_{\text{Group 1}}=14.60$). (Table 4) The highest effects of CIRS-G severity degree on SF-36 SFC values are noticed for all comorbidity parameters in the group 6 months post discharge (musculoskeletal impairment-$\eta^2_{\text{Group 4}}=4.55$; neurological impairment-$\eta^2_{\text{Group 4}}=12.32$ and cognitive impairment-$\eta^2_{\text{Group 4}}=27.20$). (Table 4)

### Table 2. Statistical interpretation of SF-36 SFC during the rehabilitation treatment for same CIRS-G severity degree.

| Evaluated groups | CIRS-G (degree) | Musculoskeletal impairment | Neurological impairment | Cognitive impairment |
|------------------|-----------------|----------------------------|------------------------|---------------------|
|                  | N (F value)     | N (F value)                | N (F value)            |
| **Groups 1-4**   |                 |                            |                        |
| 0                | 62              | 87.168**                  | 147                    | 151.851**           |
|                  | 1               | 44.313**                  | 17                     | 10.828**            |
|                  | 2               | 37                        | 14                     | 0.712               |
|                  | 3               | 29                        | 17                     | 12.685**            |
|                  | 4               | 0                         | 8                      | 4.704**             |

**Oneway ANOVA: *p<0.05; **p<0.01.**

### Table 3. Correlations of SF-36 SFC values in defined severity degree of CIRS-G regarding the time of observation.

| CIRS-G (degree) | Evaluated groups | Musculoskeletal impairment† | Neurological impairment† | Cognitive impairment† |
|-----------------|------------------|-----------------------------|-------------------------|----------------------|
| 0               | Groups 1/2       | 0.783                       | 0.820                   | 0.794                |
|                 | Groups 1/3       | 0.622                       | 0.742                   | 0.696                |
|                 | Groups 1/4       | 0.581                       | 0.696                   | 0.633                |
|                 | Groups 2/3       | 0.765                       | 0.895                   | 0.862                |
|                 | Groups 2/4       | 0.765                       | 0.843                   | 0.789                |
| 1               | Groups 1/2       | 0.867                       | 0.858                   | 0.846                |
|                 | Groups 1/3       | 0.837                       | 0.837                   | 0.735                |
|                 | Groups 1/4       | 0.789                       | 0.765                   | 0.653                |
|                 | Groups 2/3       | 0.919                       | 0.903                   | 0.904                |
|                 | Groups 2/4       | 0.877                       | 0.766                   | 0.814                |
| 2               | Groups 1/2       | 0.796                       | 0.919                   | 0.786                |
|                 | Groups 1/3       | 0.740                       | 0.765                   | 0.501                |
|                 | Groups 1/4       | 0.655                       | 0.683                   | 0.791                |
|                 | Groups 2/3       | 0.903                       | 0.905                   | 0.936                |
|                 | Groups 2/4       | 0.828                       | 0.826                   | 0.864                |
| 3               | Groups 1/2       | 0.876                       | 0.816                   | 0.800                |
|                 | Groups 1/3       | 0.849                       | 0.792                   | 0.826                |
|                 | Groups 1/4       | 0.849                       | 0.715                   | 0.712                |
|                 | Groups 2/3       | 0.892                       | 0.820                   | 0.765                |
|                 | Groups 2/4       | 0.825                       | 0.776                   | 0.746                |
| 4               | Groups 1/2       | -                           | 0.851                   | 0.912                |
|                 | Groups 1/3       | -                           | 0.830                   | 0.946                |
|                 | Groups 1/4       | -                           | 0.646                   | 0.924                |
|                 | Groups 2/3       | -                           | 0.715                   | 0.868                |
|                 | Groups 2/4       | -                           | 0.646                   | 0.843                |

†Pearson correlation coefficient.

### DISCUSSION

It is pointed out from the results of our study that the social functioning values measured by the SF-36 in elderly after hip fracture are not significantly influenced by the type of observed impairment (musculoskeletal, neurological and cognitive), while severity of the degree of CIRS-G influences significantly on social functioning recovery in groups of patients with neurological and cognitive impairments throughout entire follow-up and on long-term recovery for the group of patients with musculoskeletal impairment. These observations are consistent with previous studies which indicated comorbidity as the important predictor of mobility in patients with hip fracture. Previously it was stressed out as well, that cognitive function is among most important prognostic factors in rehabilitation outcome for these patients. Numerous studies have highlighted the positive effects of rehabilitation treatment in functional outcome of elderly patients after hip fracture. This is of particular importance since most of these patients suffer from, to the certain extent, a decrease in physical functioning and thus overall quality of life that might influence social functioning as well. Therefore, improvement in various functional abilities that would alter mobility could possibly influence improvement as well, in social functioning of elderly after hip fracture. The benefit of extended exercise rehabilitation for these patients was stressed out in the study of Auais et al., where authors noticed that such program has an impact on different functional abilities. Our results are consistent with previous observation, and have proved the efficacy of rehabilitation program in social function improvement, independent of presence of observed joined impairments.

We have demonstrated that the increase in CIRS-G severity degree for the group of patients with musculoskeletal impairment correlates closely with social functioning only for the group of patients 6 months post discharge, while for the group of patients with neurological and cognitive impairments CIRS-G severity degree correlated closely with social functioning through entire follow-up of such patients. The effects size of CIRS-G severity degrees for cognitive impairment on SFC SF-36 component values were among highest, particularly in the groups 3 and 6 months post discharge ($\eta^2_{\text{Group 3}}=22.92\%$ and $\eta^2_{\text{Group 4}}=27.20\%$). The weakest effects size of CIRS-G severity degrees for musculoskeletal impairment on SFC SF-36 component values were through entire follow-up.

Our findings are consistent with previous reports, particularly concerning cognitive impairment, since we have noticed that it is negative predictor of improvement in social functioning and thus recovery during rehabilitation program (short term) and over the period of follow-up (long term).
CONCLUSIONS

Different degrees of observed impairments (comorbidities) influence the degree of social functioning recovery in elderly after hip fracture. Therefore, individual approach as well as continuous implementation of rehabilitation program is of great importance in recovery period after hip fracture. Both short term and long term rehabilitation programs are shown to be beneficial, thus they should be mandatory for treatment of these patients particularly in domains of social functioning improvement regardless of present comorbidity, ultimately affecting and improving the one’s quality of life.

AUTHORS’ CONTRIBUTION: Each author contributed individually and significantly to the development of the study. NR (0000-0001-6454-390x)* and DN (0000-0002-0609-9916)* were the main contributors for study design and the drafting of the manuscript. ML (0000-0002-1879-4190)*, MH (0000-0003-1308-0727)*, NR and OIS (0000-0002-2217-8868)* underwent diagnostics procedures, followed patients and gathered clinical data. DN and ML evaluated the data of the statistical analysis. NR, MH, OIS and DN performed the literature search, review of the manuscript and contributed to the intellectual concept of the study. *ORCID (Open Research and Contributor ID).

REFERENCES

1. Hoogerduijn JG, Schuurmans MJ, Duijnste MS, de Rooij SE, Grypdonck MF. A systematic review of predictors and screening instruments to identify older hospitalized patients at risk for functional decline. J Clin Nurs. 2007;16(1):46-57.
2. Wasdi T. [Functional decline in older people]. Nihon Rinsho. 2013;71(10):1727-32.
3. Ishizaki T, Watanabe S, Suzuki T, Shibata H, Haga H. Predictors for functional decline among nondisabled older Japanese living in a community during a 3-year follow-up. J Am Geriatr Soc. 2000;48(11):1424-9.
4. Sarkisian CA, Liu H, Gutierrez PR, Seeley DG, Cummings SR, Mangione CM. Modifiable risk factors predict functional decline among older women: a prospectively validated clinical prediction tool. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000;48(2):170-8.
5. Radosavljevic N, Nikolic D, Lazovic M, Petronic I, Milicicic V, Radosavljevic Z, et al. Estimation of functional recovery in patients after hip fracture by Berg Balance Scale regarding the sex, age and comorbidity of participants. Geriatr Gerontol Int. 2013;13(2):365-71.
6. Radosavljevic N, Lazovic M, Nikolic D, Petronic I, Radosavljevic Z, Jeremic A. Influence of selective comorbidity predictors on functional recovery after hip fracture in an older population. Biomed Pap Med Fac Univ Palacký Olomouc Czech Repub. 2012;156(4):365-70.
7. Radosavljevic N. The effects of balneo-physical therapy on the quality of life of patients who underwent surgery for hip fractures [dissertation]. Belgrade: Faculty of Medicine; 2013.
8. González-Zabaleta J, Pita-Fernandez S, Seoane-Pillado T, López-Calviño B, Gonzalez-Zabaleta JL. Comorbidity as a predictor of mortality and mobility after hip fracture. Geriatr Gerontol Int. 2016;16(6):561-9.
9. Hershkovitz A, Kalanderiov Z, Hermush V, Weiss R, Brill S. Factors affecting short-term rehabilitation outcomes of disabled elderly patients with proximal hip fracture. Arch Phys Med Rehabil. 2007;88(7):916-21.
10. Taggart HM. Rehabilitation after a hip fracture. Special needs of the elderly. Crit Care Nurs Clin North Am. 2001;13(3):411-9.
11. Lógters T, Hakimri M, Lihart W, Kaiser T, Briem D, Rueger J, et al. [Early interdisciplinary geriatric rehabilitation after hip fracture : Effective concept or just transfer of costs?]. Unfallchirurg. 2008;111(9):719-26.
12. Sherrington C, Tiedemann A, Cameron I. Physical exercise after hip fracture: an evidence overview. Eur J Phys Rehabil Med. 2011;47(2):297-307.
13. Auala MA, Eilayyan O, Mayo NE. Extended exercise rehabilitation after hip fracture improves patients’ physical function: a systematic review and meta-analysis. Phys Ther. 2012;92(11):1437-51.
14. Söderqvist A, Miedel R, Porzner S, Tidermark J. The influence of cognitive function on outcome after a hip fracture. J Bone Joint Surg Am. 2006;88(10):2115-23.
15. Al-Ani AN, Fedin L, Söderqvist A, Ackermann P, Samnegård E, Dalén N, et al. Does rehabilitation matter in patients with femoral neck fracture and cognitive impairment? A prospective study of 246 patients. Arch Phys Med Rehabil. 2010;91(1):51-7.